Immuneering Corporation (IMRX), a late-stage clinical oncology company, is expected to present updated data from its Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in treating pancreatic cancer at the annual meeting of the American Society of Clinical Oncology (ASCO) on June 1, 2026.
Atebimetinib (IMM-I-104) is a once-daily, oral, investigational Deep Cyclic inhibitor of MEK that provides more durable anti-tumor activity to improve survival across different indications, including pancreatic cancer.
The Phase 2a trial evaluates atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) to treat patients with advanced or metastatic pancreatic cancer as a first-line treatment. The presentation will include survival data across 55 first-line patients, comprising the initial cohort of 34 patients and an additional 21 patients.
The company is advancing atebimetinib, and expects to initiate a Phase 3 trial in combination with chemotherapy for treating pancreatic cancer, dubbed MAPKeeper trial by mid-2026.
IMRX closed Tuesday at $5.55, up 0.36%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.